MannKind | MNKD - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Adma Biologics USD 64.2M 12.21M 2026-03
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Insmed USD 526.79M 20.55M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
MannKind USD 110.21M 690K 2026-06
Merck USD 15.77B 2.4B 2026-06
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Novavax USD 126.2M 23.62M 2025-12
Novo Nordisk DKK 6.96B 30.25B 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Sanofi EUR 9.92B 607M 2026-06
Xencor USD 87.82M 5.44M 2026-06